NEWS OUT: DVLP Issues Shareholder Letter on Increased Growth Potential Following Recent CBD Acquisition
DENVER, March 26, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Golden Developing Solutions, Inc. (DVLP) (“DVLP” or the “Company”), an emerging leader in the Cannabis, Hemp, and CBD marketplace, issues the following letter to Shareholders from the CEO:
Dear Valued Shareholder,
First off, I want to begin by expressing our gratitude to all of our committed shareholders as we push through a period that we believe is laying a powerful foundation for increasing upside potential as an emerging diversified leader in the cannabis and CBD markets.
As you know, we have secured powerful traction in the cannabis space as a service provider with our popular Where’s Weed app and portal. And, recently, we expanded this market coverage footprint by moving into the CBD space full force with our Where’s CBD portal, which is beginning to take root as a powerful resource.
That sets the stage for what we feel could be a true gamechanger in the quarters ahead, in terms of synergies and overall augmentation of our core growth proposition: our recent acquisition of Infusionz, LLC (“CBD Infusionz”), a premium manufacturer of high quality CBD products.
Why do we believe this acquisition is such an important move?
First off, it will immediately augment our topline growth data, which is a core factor for institutional investors in search of strong growth potential. We can now offer a better argument given the strong revenues we assume as we onboard CBD Infusionz. For example, if we backdate our analysis, the combined entity would have had total sales of more than $500K in February alone.
In addition, following this acquisition, we have a fully developed retail, wholesale, distribution, and white labeling operation in the CBD space to augment our Where’s CBD services offering.
In fact, with CBD Infusionz operationally integrated, we will now have on offer more than 150 product SKU’s, including vegan products, pet products, pre-rolls, concentrates, creams and lotions, muscle freeze, massage oil, and premium products with existing brand traction such as the Saucy Boss Concentrate line and the Terpy J Pre-roll line.
In short, we emerge from this deal with a powerful value proposition for new investment capital. Our equity is now trading at just 2X our 2019 projected sales, which represents a run rate of $6 million on an annualized basis at current levels. That run rate is also a fixed point on a steep growth curve that shows evidence of a 4-6 month doubling rate at present.
And, perhaps most importantly, we are tethered to arguably the two most robust growth markets on the planet right now in cannabis and CBD. Following this acquisition, we are now more focused on CBD than we have been in the past because the growth curve is even more robust in CBD than it is in cannabis, given the lack of legal barriers to mainstream adoption by consumers in North America. Recent updated forecasts now anticipate a twenty-fold ramp in total sales volume over the next 36 months in the CBD marketplace to over $20 billion, according to several prominent forecasts.
In other words, we believe, with our recent acquisition of CBD Infusionz, we have assembled the pieces of a very strong shareholder value proposition over coming quarters and years.
We will continue to act according to the principles that have taken us this far. We have a number of exciting plans in the works, and we will do our best to keep you updated as we move forward.
Best Regards,
Stavros Triant, CEO
